Investors owning 31 percent of shares of Allergan Inc have asked the company to call a special shareholder meeting, activist shareholder William Ackman said on Friday, giving the hedge fund manager a victory in his fight to acquire the Botox maker.
Tags: Valeant Pharmaceuticals
Ackman Established Superiority On Pershing By Raising Its Stake In Valeant Pharmaceuticals
The billionaire investor Mr. Ackman's Pershing Square Capital Management was one of the largest stock holders of Valeant Pharmaceuticals. Ackman has perceptively made his position in Valeant far more important by raising its stake from 5.7% to 9.9% recently. Now, Pershing is the second largest shareholder in Valeant followed by Sequoia Fund led by Ruane, Goldfarb and Cuniff.
Valeant partners with AstraZeneca for psoriasis drug
Valeant Pharmaceuticals, Inc. of Canada has partnered with AstraZeneca for the selling rights of psoriasis drug brodalumab. Amgen Inc. ended its partnership with AstraZeneca due to its worries over the drug's side effects.
ValueAct buys 5.1 percent stake in Baker Hughes
Activist hedge fund ValueAct Capital disclosed a 5.1 percent stake in Baker Hughes Inc (BHI.N), the world's No. 3 oilfield services company that has agreed to be bought by bigger rival Halliburton Co (HAL.N) for $35 billion in cash and stock.
Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source
Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.
Latest News
Valeant Pharmaceuticals and energy sector boost TSX The Toronto Stock Exchange's S&P/TSX composite index, Canada's main stock index, hit 12,217.
Valeant purchases Bausch & Lomb to create business unit that can generate US$3.5 billion in net revenue.
Valeant Pharmaceuticals is in discussion to acquire Actavis for about US$13 billion. Valeant Pharmaceuticals International Inc, the largest publicly listed drug maker in Canada, is in discussion to purchase generics pharmaceutical firm Actavis Inc for US$13 billion.
1
